Key result
Homocysteine-lowering therapy with B-vitamins fails to reduce cardiovascular disease risk in large RCTs.
Answers are grounded in this paper and cite their sources.
Cardiovascular disease (CVD) is a major cause of morbidity and mortality in developed countries. However, traditional risk factors cannot fully account for this. In the last 20 years, there has been an explosion of interest in plasma total homocysteine (tHcy) as a potential modifiable risk factor for CVD. Recent meta-analyses of epidemiological studies support the concept that increased tHcy concentrations are associated with CVD. This has led to the 'homocysteine hypothesis', which states that lowering plasma tHcy using folic acid and other B-vitamins will reduce the risk of CVD. In experimental studies, homocysteine has been shown to cause oxidative stress, endothelial cell dysfunction and promote thrombogenesis. However, data from recent large randomized controlled trials have shown that there is no clinical benefit to lowering plasma tHcy concentrations with folic acid and other B-vitamins. This lack of effect of tHcy lowering strongly suggests that homocysteine is not an instigator but merely an indicator of CVD.
No takes yet. Share an insight, caveat, or question.
Stuart J. Moat (2008) conducted a review in Cardiovascular disease. Folic acid and B-vitamins to lower plasma total homocysteine was evaluated on Cardiovascular disease risk. Lowering plasma total homocysteine with folic acid and B-vitamins showed no clinical benefit in reducing cardiovascular disease risk in large RCTs, suggesting it is an indicator rather than a cause.
Synapse has enriched 10 related papers. Consider them for comparative context: